Your session is about to expire
← Back to Search
Gevokizumab + Standard Cancer Therapy for Colorectal and Gastroesophageal Cancers
Study Summary
This trial will study the best dose of gevokizumab to combine with standard cancer therapies for treating metastatic colorectal, gastroesophageal, and renal cell carcinomas.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 1 & 2 trial • 8 Patients • NCT01835132Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your blood test shows high levels of a protein called hs-CRP.My colorectal cancer is in its first stage of spreading.I have a weakened immune system or an infection.I am not taking any medications that are not allowed in the study.I have brain metastases that cause symptoms or need specific treatment.I have clear-cell renal cancer, treated with an anti-angiogenic agent but it progressed.My cancer has spread, cannot be removed by surgery, and I have tissue samples available.Your blood test shows high levels of a protein called hs-CRP.I do not have conditions that increase my bleeding risk with anti-VEGF treatments.I am not taking any strong medication or supplements that affect liver enzymes.My stomach or esophagus cancer has worsened after first-line chemotherapy including platinum and fluoropyrimidine.I have a GI condition that could affect how my body absorbs medication.I have at least one tumor that can be measured on a scan.I haven't had serious heart problems in the last 6 months.My colorectal cancer has worsened after first-line treatment including a fluoropyrimidine and oxaliplatin.
- Group 1: Cohort A: 1st line colorectal cancer
- Group 2: Cohort B: 2nd line colorectal cancer
- Group 3: Cohort C: 2nd line gastroesophageal cancer
- Group 4: Cohort D: 2nd or 3rd line renal cell carcinoma
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical issues can be addressed with Gevokizumab?
"Gevokizumab can be employed to fight malignant neoplasms, rectal carcinoma, and colorectal carcinoma."
What effects does Gevokizumab have on human health and wellbeing?
"Due to the preliminary nature of Gevokizumab clinical trials, it was assigned a score of 1 for safety. This reflects lack of data concerning both efficacy and harm reduction potential."
What is the limit of enrollees for this clinical study?
"Indeed, the information on clinicaltrials.gov affirms that this medical trial is in active recruitment mode. It was initiated on May 22nd 2019 and has been updated as recent as October 24th 2022. The project aims to recruit 172 patients at a single site."
What other experimental studies have included Gevokizumab?
"To date, 1737 clinical trials are researching Gevokizumab with 464 in the third phase. While a number of these studies originate from Guangzhou, Guangdong, there is actually an expansive network of 85098 different sites conducting trials for this particular drug."
Are there still openings available to join this research endeavor?
"Clinicaltrials.gov has confirmed that this investigation is currently recruiting patients, having originally been posted on the 22nd of May 2019 and most recently amended on October 24th 2022."
What is the primary goal of this medical experiment?
"This clinical trial, spanning 40 weeks in duration, seeks to evaluate the safety of a drug by assessing the number of dose limiting toxicities (DLTs). Secondary metrics include overall response rate, overall survival and disease control rate according to RECIST v1.1 standards."
Share this study with friends
Copy Link
Messenger